如何治疗重型遗传性抗凝血酶缺乏症:来自抗凝血酶布达佩斯3型纯合子病例的经验
本文从西班牙、比利时和匈牙利参考中心25年间699例抗凝血酶缺乏症患者中选取病例,以2例抗凝血酶布达佩斯3型纯合子患者为例,总结该病的临床特征、诊断流程和管理,并针对肝素抵抗、腔静脉异常和产科并发症等缺乏正式循证指南的特殊临床场景提出专家建议。
要点
- 抗凝血酶布达佩斯3型(p.Leu131Phe)是欧洲最常见的II型/肝素结合位点缺陷,尤其在罗姆人群中。
- 纯合子患者抗凝血酶活性极低(<20%),表现为幼年和复发性静脉血栓栓塞。
- 肝素抵抗、腔静脉异常和产科并发症等特殊场景在纯合子患者中可能更常见,原文提出专家建议。
核心结论
- 抗凝血酶缺乏症是最严重的遗传性易栓症之一,由于当前诊断算法的局限性和患者人群临床异质性高,该病可能被低估。
- 以抗凝血酶布达佩斯3型纯合子病例为例,可总结重型抗凝血酶缺乏症的临床特征、诊断流程和管理,并针对缺乏正式循证指南的特殊临床场景提出专家建议和未来展望。
研究设计与样本
- 从西班牙、比利时和匈牙利参考中心25年间招募的699例抗凝血酶缺乏症患者中选取病例。
- 以2例抗凝血酶布达佩斯3型纯合子患者为例进行病例分析。
主要发现
- 2例纯合子患者抗凝血酶活性极低(<20%),表现为幼年和复发性静脉血栓栓塞。
- 这些病例再现了治疗抗凝血酶缺乏症患者时可能遇到的诸多问题。
- 肝素抵抗、腔静脉异常和产科并发症等特殊临床场景在纯合子患者中可能更常见,且无正式循证指南。
关键数值与推荐
- 抗凝血酶布达佩斯3型(p.Leu131Phe)是欧洲最常见的II型/肝素结合位点缺陷,尤其在罗姆人群中,存在纯合子个体。
- 杂合子I型(定量)变异通常与严重易栓表型相关;杂合子II型(定性)变异异质性大,其中肝素结合位点缺陷为轻度/中度且最常见。
- 纯合子患者抗凝血酶活性<20%,表现为幼年和复发性静脉血栓栓塞。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antithrombin deficiency represents one of the most severe inherited thrombophilias. Albeit a rare disorder, available knowledge suggests that antithrombin deficiency is underestimated due to the limitations of current diagnostic algorithms. The high clinical variability of this patient population may be another cause of underdiagnosis. Heterozygous type I (quantitative) variants are normally associated with a severe thrombophilic phenotype, while heterozygous type II (qualitative) variants are heterogeneous, including heparin-binding site defects, which are mild/moderate and the most prevalent. Antithrombin Budapest 3 (p.Leu131Phe) is the most frequent type II/heparin-binding site deficiency in Europe, particularly in the Roma population, with a remarkable existence of homozygous subjects. OBJECTIVES: To determine the clinical features, diagnostic procedures, and management of patients with severe antithrombin deficiency, leveraging the study of cases homozygous for the antithrombin Budapest 3 variant. METHODS: Patients were selected from 699 subjects with antithrombin deficiency and recruited over 25 years from reference centers in Spain, Belgium, and Hungary. RESULTS: Guided by 2 illustrative cases with homozygous antithrombin Budapest 3, we report the spectrum and clinical management of patients with this disorder. These cases, with very low antithrombin activity (<20%) and juvenile and recurrent venous thromboembolism, recapitulate numerous issues that one might encounter when treating patients with antithrombin deficiency. In addition, special clinical scenarios for which no formal evidence-based guidelines exist might be found more frequently in these patients, including heparin resistance, vena cava anomalies, and obstetric complications. CONCLUSION: Expert proposals on the optimal management of these controversial areas, as well as future perspectives, are also formulated.
引用
- Bravo-Pérez C, Corral J, Orlando C, et al. How we treat severe inherited antithrombin deficiency: lessons from cases homozygous for the Budapest 3 variant. J Thromb Haemost. 2025. PMID: 39933654. doi:10.1016/j.jtha.2025.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。